Exhibit 10.2

***Text Omitted and Filed Separately

 with the Securities and Exchange Commission.

Confidential Treatment Requested
Under 17 C.F.R. Sections 200.80(b)(4)
and 240.24b-2

 

AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT

This Amendment No. 1 to the Collaboration and License Agreement (“this
Amendment”), is entered into as of September 21, 2016 (the “Amendment No. 1
Effective Date”) by and between Xencor, Inc., a corporation organized and
existing under the Laws of the State of Delaware (“Xencor”), and Novartis
Institutes for BioMedical Research, Inc., a corporation organized and existing
under the Laws of the State of Delaware (“Novartis”). Xencor and Novartis are
referred to in this Agreement individually as a “Party” and collectively as the
“Parties”.

RECITALS:

WHEREAS, The Parties previously entered into the Collaboration and License
Agreement with an effective date of June 26, 2016 (the “Agreement”).

WHEREAS, The Parties wish to amend the terms of the Agreement.

NOW, THEREFORE, in consideration of the foregoing premises and the mutual
covenants herein contained, the Parties hereby agree as follows:

1.

Section 1.1.124 shall be replaced with the following:

1.1.124“Internal Program” means, […***…]

 

 

***Confidential Treatment Requested

1.

 

--------------------------------------------------------------------------------

 

 

[…***…].

2.

Except as expressly provided in this Amendment, all other terms, conditions and
provisions of the Agreement shall continue in full force and effect as provided
therein.

3.

The Amendment will be construed and the respective rights of the Parties
determined in accordance with the substantive Laws of the State of New York,
notwithstanding any provisions of New York Law or any other Law governing
conflicts of laws to the contrary.

4.

The Amendment may be executed in two counterparts, including by facsimile or PDF
signature pages, each of which will be deemed an original, but both of which
together will constitute one and the same instrument.

THE REMAINDER OF THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK

 

 

***Confidential Treatment Requested

2.

 

--------------------------------------------------------------------------------

 

 

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment
No. 1 Effective Date.

 

 

 

 

 

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

 

XENCOR, INC.

 

 

 

 

 

BY

/s/ Scott Brown

 

BY:

/s/ Edgardo Baracchini

NAME:

Scott Brown

 

NAME:

Edgardo Baracchini

TITLE:

Vice President, General Counsel

 

TITLE:

C.B.O.

 

 

3.

 

--------------------------------------------------------------------------------